Alzheimer's Drug Discovery Foundation To Host The 3rd Drug Discovery For Neurodegeneration Conference

Main Category: Alzheimer's / Dementia
Also Included In: Neurology / Neuroscience
Article Date: 14 Jan 2009 - 5:00 PDT

email to a friend   printer friendly   opinions  

Twenty-eight international leaders in the field of neurodegenerative disease drug discovery will speak in Washington, DC on February 2-3, 2009 for the 3rd Drug Discovery for Neurodegeneration conference.

The Alzheimer's Drug Discovery Foundation's (ADDF) meeting focuses on the complex process of translating basic research into novel therapies for neurodegeneration by providing participants with resources about this field of scientific investigation while addressing the associated barriers and challenges.

The conference is organized around six sub-topics: Basics of Medicinal Chemistry; Hits & Leads; Pre-Clinical Proof-of-Concept & Development; Issues in Technology Transfer; Ask the Experts: Drug Discovery for Neurodegenerative Diseases; and Resources and Services for Advancing Drug Discovery. Speakers will present lectures and case studies on Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS) and other 'orphan' neurological diseases.

The annual meeting attracts a multi-disciplinary network of academic and industry scientists engaged in drug discovery research for neurodegenerative diseases, business development and licensing professionals, alliance management professionals, venture capitalists and other investors.

This conference is presented by the ADDF and is also supported by a conference grant: U13-AG031125 from the National Institute on Aging, the National Institute of Neurological Disorders and Stroke and the NIH Office of Rare Diseases.

About the Alzheimer's Drug Discovery Foundation (ADDF)

ADDF is the only public charity whose sole mission is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. ADDF uses a venture philanthropy model to bridge the worldwide funding gap between basic research and later-stage development, using any return on investment to support new research. Since 1998, we have granted more than $35M to fund over 240 Alzheimer's drug discovery programs in academic centers and biotechnology companies in 12 countries.

Alzheimer's Drug Discovery Foundation

• Additional
• References
• Citations